Stay up To date. Experts commentary

Extrahepatic Cancers Are the Leading Cause of Death in Patients Achieving Hepatitis B Virus Control or Hepatitis C Virus Eradication
20/11/2018 - by François Raffi
Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease & Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes
05/03/2018 - by François Raffi
Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
25/01/2018 - by Alessandra Mangia
Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus.
15/01/2018 - by Maria Buti
Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study.
28/09/2017 - by Susanna Naggie
DAA-associated HBV reactivation: from the warning to the daily practice - To treat or not to treat
16/08/2017 - by Stanislas Pol
American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
19/07/2017 - by François Raffi
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
05/07/2017 - by Alessandra Mangia
Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death
20/06/2017 - by Stanislas Pol
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
10/05/2017 - by Jordan Feld
Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.
10/05/2017 - by Jordan Feld
Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.
10/05/2017 - by Jordan Feld
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
25/04/2017 - by Maria Buti
Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
05/04/2017 - by Jürgen Rockstroh
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
28/03/2017 - by Jürgen Rockstroh
EDITORIAL PERSPECTIVE: HCV cure is associated with a global hepatic and extra-hepatic- benefit, still questions on hematological malignancies long-term risk !
17/03/2017 - by Stanislas Pol
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
24/02/2017 - by Jordan Feld
Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications.
06/02/2017 - by Stanislas Pol
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.
25/01/2017 - by Jordan Feld
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
12/01/2017 - by Alessandra Mangia
New EASL Recommendations, presented at the Paris Special Conference in Sept 2016, just published in Journal of Hepatology 2017 ; 66:153-94.
04/01/2017
Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.
15/12/2016 - by Jürgen Rockstroh
EDITORIAL PERSPECTIVE: Kidney Transplant Recipients With Chronic HCV Infection: A Population to prioritize for HCV cure.
05/12/2016 - by Stanislas Pol
The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma : Data from three ANRS cohorts.
28/11/2016 - by Stanislas Pol
Risk of Hepatocellular Carcinoma After Sustained Virological Response in Veterans With Hepatitis C Virus Infection.
05/10/2016 - by Jordan Feld
Statin Drugs Decrease Progression to Cirrhosis in HIV/HCV Co-infected Individuals.
27/09/2016 - by Susanna Naggie
Atorvastatin and Fluvastatin Are Associated With Dose-Dependent Reductions in Cirrhosis and Hepatocellular Carcinoma, Among Patients With Hepatitis C Virus: Results From ERCHIVES.
27/09/2016 - by Maria Buti
Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
13/09/2016 - by Susanna Naggie
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
02/09/2016 - by François Raffi
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
26/07/2016 - by Jordan Feld
Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens.
18/07/2016 - by Alessandra Mangia
Factors Associated with Spontaneous Clearance of Chronic Hepatitis C Viru Infection: a Retrospective Case Control Study.
04/07/2016 - by Jürgen Rockstroh
Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
27/06/2016 - by Susanna Naggie
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
05/06/2016 - by Maria Buti
Hepatitis C reinfection after sustained virological response.
25/05/2016 - by Alessandra Mangia
Hepatitis C virus as a systemic disease: reaching beyond the liver.
13/05/2016 - by François Raffi
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
01/05/2016 - by Stanislas Pol
Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C–Related Compensated Cirrhosis.
10/04/2016 - by Jürgen Rockstroh
HCV Vertical Transmission in Pregnancy: New Horizons in the Era of DAAs.
15/03/2016 - by Susanna Naggie
WHO early release of HCV treatment recommendations, February 24, 2016.
03/03/2016 - by François Raffi
Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies.
22/02/2016 - by Maria Buti
Updated HCV guidelines released on February 24, 2016 by AASLD and IDSA.
28/02/2016 - by François Raffi
Bradyarrhythmias and direct acting (DAAs).
11/02/2016 - by Stanislas Pol
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program.
01/02/2016 - by Alessandra Mangia
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
16/01/2016 - by François Raffi
MELD Score Kinetics in Decompensated HIV+/HCV+ Patients. A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study).
05/12/2015 - by Jürgen Rockstroh
Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.
23/11/2015 - by Stanislas Pol
Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients?
11/11/2015 - by Susanna Naggie
Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy.
02/11/2015 - by Maria Buti
HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: it’s time to end segregation and integrate HIV patients into HCV Trials.
20/10/2015 - by François Raffi
Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
30/09/2015 - by Dominique Salmon
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
02/09/2015 - by Maria Buti
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.
25/08/2015 - by Jürgen Rockstroh
EDITORIAL
21/08/2015 - by Stanislas Pol